Duchenne Muscular Dystrophy Clinical Trial

Completed · Not applicable · Has a placebo group

Conditions studied: Duchenne Muscular Dystrophy

In brief

The primary objective of this investigation is to assess the effectiveness of transcutaneous electrical nerve stimulation applied using VECTTOR to reduce the symptoms of Duchenne Muscular Dystrophy and reduce the impact of DMD upon the participants' quality of life. The primary outcome measures will include: 1. increased muscle strength, 2. increased range of joint motions and 3. improved sleep parameters of ASI, N3 and REM.

Key facts

Study ID

NCT01874275

Run by

Alan Neuromedical Technologies, LLC

People needed

6

Starts

2013-06-01

Expected to finish

2014-09-01

Last updated by the study team

2015-05-04

Who can join

Age: 8 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have Duchenne Muscular Dystrophy diagnosis as confirmed by licensed physician, wheelchair bound, \& age 8 - 20 years old.

You may not qualify if…

• Active cancer in the area of application of the treatment, infection, skin infection, pregnancy, thrombophlebitis, pacemaker, amputation of any part of feet or hands, taking steroids. In addition, the participant may not be in any other clinical trial during the time they are in this study.

Where it is running

• Alan Neuromedical — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.